Efficacy of next treatment received after Nivolumab (Nivo) progression in patients (pts) with non-small-cell lung cancer (NSCLC)

被引：0
|
作者：
Costantini, Adrien
Corny, Jennifer
Fallet, Vincent
Renet, Sophie
Friard, Sylvie
Chouaid, Christos
Duchemann, Boris
Giroux-Leprieur, Etienne
Taillade, Laurent
Doucet, Ludovic
Wislez, Marie
Tredaniel, Jean
Cadranel, Jacques
Jouveshomme, Stephane
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.OA1476
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
OA1476
引用
收藏
页数：1
相关论文
共 50 条
  • [41] BEVACIZUMAB AS A SALVAGE TREATMENT IN HEAVILY PRETREATED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS
    Hadoux, J.
    Angelergues, A.
    Bidault, F.
    Soria, J.
    Planchard, D.
    Le Chevalier, T.
    Massard, C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2010, 21 : 151 - 151
  • [42] Safety and feasibility of radiotherapy treatment in elderly non-small-cell lung cancer (NSCLC) patients
    Fiorica, F.
    Cartei, F.
    Ursino, S.
    Stefanelli, A.
    Zagatti, Y.
    Berretta, S.
    Figura, S.
    Maugeri, D.
    Zanet, E.
    Sparta, D.
    La Morella, C.
    Tirelli, U.
    Berretta, M.
    ARCHIVES OF GERONTOLOGY AND GERIATRICS, 2010, 50 (02) : 185 - 191
  • [43] Nivolumab plus Ipilimumab in Non-Small-Cell Lung Cancer
    Bersanelli, Melissa
    Tiseo, Marcello
    Banna, Giuseppe L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (09): : 874 - 875
  • [44] Effect and biomarker of Nivolumab for non-small-cell lung cancer
    Wang, Li
    Zhao, Deze
    Qin, Kang
    Ul Rehman, Faisal
    Zhang, Xiaochun
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 117
  • [45] Perioperative Nivolumab and Chemotherapy in Non-Small-Cell Lung Cancer
    Verma, Saurav
    Vincent, Mark
    Breadner, Daniel
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (16): : 1534 - 1534
  • [46] Nivolumab plus ipilimumab in non-small-cell lung cancer
    Reck, Martin
    Borghaei, Hossein
    O'Byrne, Kenneth J.
    FUTURE ONCOLOGY, 2019, 15 (19) : 2287 - 2302
  • [47] Nivolumab in non-small-cell lung cancer with EGFR mutation
    Yoshida, H.
    Kim, Y. H.
    Ozasa, H.
    Nagai, H.
    Sakamori, Y.
    Tsuji, T.
    Nomizo, T.
    Yasuda, Y.
    Funazo, T.
    Hirai, T.
    ANNALS OF ONCOLOGY, 2018, 29 (03) : 777 - 778
  • [48] Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC)
    Cappuzzo, F
    Bartolini, S
    Ceresoli, GL
    Tamberi, S
    Spreafico, A
    Lombardo, L
    Gregorc, V
    Toschi, L
    Calandri, C
    Villa, E
    Crinò, L
    BRITISH JOURNAL OF CANCER, 2004, 90 (01) : 82 - 86
  • [49] Bone Metastases and Efficacy of Immunotherapy in Patients with Pretreated Advanced Non-Small-Cell Lung Cancer (NSCLC)
    Landi, L.
    D'Inca, F.
    Cortesi, E.
    Chiari, R.
    Grossi, F.
    Delmonte, A.
    De Marinis, F.
    Signorelli, D.
    Dazzi, C.
    Sperandi, F.
    Catino, A.
    Giannarelli, D.
    Parra, H. Soto
    Minuti, G.
    Bordi, P.
    Migliorino, M. R.
    Palla, A.
    Tonini, G.
    Cognetti, F.
    Santoro, A.
    Tassinari, D.
    Scoppola, A.
    Bidoli, P.
    Piantedosi, F.
    Maio, M.
    Crino, L.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S481 - S481
  • [50] Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
    Subramanian, J.
    Moreno, V.
    Bosch-Barrera, J.
    Pikiel, J.
    Kristeleit, R.
    Guo, W.
    Danaee, H.
    Im, E.
    Roda, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S886 - S887
12345